<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hillemanns, Peter</style></author><author><style face="normal" font="default" size="100%">Klaus Friese</style></author><author><style face="normal" font="default" size="100%">Christian Dannecker</style></author><author><style face="normal" font="default" size="100%">Stefanie Klug</style></author><author><style face="normal" font="default" size="100%">Ulrike Seifert</style></author><author><style face="normal" font="default" size="100%">Thomas Iftner</style></author><author><style face="normal" font="default" size="100%">Juliane Hädicke</style></author><author><style face="normal" font="default" size="100%">Thomas Löning</style></author><author><style face="normal" font="default" size="100%">Lars Horn</style></author><author><style face="normal" font="default" size="100%">Dietmar Schmidt</style></author><author><style face="normal" font="default" size="100%">Hans Ikenberg</style></author><author><style face="normal" font="default" size="100%">Manfred Steiner</style></author><author><style face="normal" font="default" size="100%">Ulrich Freitag</style></author><author><style face="normal" font="default" size="100%">Uwe Siebert</style></author><author><style face="normal" font="default" size="100%">Gaby Sroczynski</style></author><author><style face="normal" font="default" size="100%">Willi Sauerbrei</style></author><author><style face="normal" font="default" size="100%">Matthias W Beckmann</style></author><author><style face="normal" font="default" size="100%">Marion Gebhardt</style></author><author><style face="normal" font="default" size="100%">Michael Friedrich</style></author><author><style face="normal" font="default" size="100%">Karsten Münstedt</style></author><author><style face="normal" font="default" size="100%">Schneider, Achim</style></author><author><style face="normal" font="default" size="100%">Kaufmann, Andreas</style></author><author><style face="normal" font="default" size="100%">K Ulrich Petry</style></author><author><style face="normal" font="default" size="100%">Axel P A Schäfer</style></author><author><style face="normal" font="default" size="100%">Pawlita, Michael</style></author><author><style face="normal" font="default" size="100%">Joachim Weis</style></author><author><style face="normal" font="default" size="100%">Anja Mehnert</style></author><author><style face="normal" font="default" size="100%">Mathias Fehr</style></author><author><style face="normal" font="default" size="100%">Christoph Grimm</style></author><author><style face="normal" font="default" size="100%">Olaf Reich</style></author><author><style face="normal" font="default" size="100%">M. Arbyn</style></author><author><style face="normal" font="default" size="100%">Jos Kleijnen</style></author><author><style face="normal" font="default" size="100%">Simone Wesselmann</style></author><author><style face="normal" font="default" size="100%">Monika Nothacker</style></author><author><style face="normal" font="default" size="100%">Markus Follmann</style></author><author><style face="normal" font="default" size="100%">Thomas Langer</style></author><author><style face="normal" font="default" size="100%">Matthias Jentschke</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Prevention of Cervical Cancer: Guideline of the DGGG and the DKG (S3 Level, AWMF Register Number 015/027OL, December 2017) - Part 2 on Triage, Treatment and Follow-up.</style></title><secondary-title><style face="normal" font="default" size="100%">Geburtshilfe Frauenheilkd</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">cervical cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">cervical intraepithelial neoplasia (CIN)</style></keyword><keyword><style  face="normal" font="default" size="100%">cervical precancerous condition</style></keyword><keyword><style  face="normal" font="default" size="100%">HPV</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2019 Feb</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">79</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;em&gt;EN&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;AIMS&lt;/strong&gt;&lt;br&gt;
Annual opportunistic screening for cervical carcinoma has been done in Germany since 1971. The creation of this S3 guideline meets an important need, outlined in the National Cancer Plan, with regard to screening for cervical cancer, as this guideline aims to provide important information and support for planned organized screening for cervical cancer in Germany.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;METHODS&lt;/strong&gt;&lt;br&gt;
With the financial support of German Cancer Aid, 21 professional societies developed evidence-based statements and recommendations (classified using the GRADE system) for the screening, management and treatment of precancerous conditions of the cervix. Two independent scientific institutes compiled systematic reviews for this guideline.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;RECOMMENDATIONS&lt;/strong&gt;&lt;br&gt;
The second part of this short summary deals with the triage, treatment and follow-up care of cervical dysplasia. With regard to those women who do not participate in screening, the guideline authors recommend sending out repeat invitation letters or an HPV self-collection kit. Colposcopy should be carried out for further investigation if cytology findings are Pap II-p and HPV test results are positive or if the results of an HPV 16 or HPV 18 screening test are positive. A single abnormal Pap smear should be triaged and investigated using HPV testing or p16/Ki67 dual staining.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;FR&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;OBJECTIFS&lt;/strong&gt;&lt;br&gt;
dépistage opportuniste annuel pour le cancer du col utérin a été fait en Allemagne depuis 1971. La création de cette ligne directrice S3 répond au besoin important, indiqué dans le Plan national du cancer en ce qui concerne le dépistage du cancer du col de l' utérus, comme cette directive vise à fournir des informations importantes et Soutien au dépistage organisé du cancer du col utérin en Allemagne.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;MÉTHODES&lt;/strong&gt;&lt;br&gt;
avec le soutien financier de German Cancer Aid, 21 sociétés professionnelles ont élaboré des déclarations et des recommandations fondées sur des preuves pour le dépistage, la gestion et le traitement des affections précancéreuses du col de l'utérus. Deux instituts scientifiques indépendants ont compilé des revues systématiques pour cette directive.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;RECOMMENDATIONS&lt;/strong&gt;&lt;br&gt;
La deuxième partie du triage, du traitement et des soins de suivi de la dysplasie cervicale. Lors du dépistage, les auteurs des lignes directrices ou les envoyer à un kit de collecte automatique du VPH. Les tests de dépistage HPP 16 ou HPV 18 sont positifs. Un seul frottis anormal doit être testé et testé avec le test HPV ou la coloration double p16 / Ki67.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue></record></records></xml>